Eniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most widely-used oncology agents. 5-FU is widely used in the U.S. and is often first or second line therapy for a variety of cancers including colorectal, br...
For the treatment of cancer in combination with 5-fluorouracil.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.